文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

临床相关脓毒症模型中持续输注抗凝血酶III

Continuous Antithrombin III Infusion in a Clinically Relevant Sepsis Model.
PubMed 文献 · Shock · 2025-07-25
一句话结论小鼠盲肠结扎穿孔脓毒症模型中,延迟6小时持续输注抗凝血酶III较生理盐水或单次弹丸注射改善7天生存率(65% vs 29% vs 19%),但仅减轻肝损伤。

该研究在小鼠盲肠结扎穿孔(CLP)脓毒症模型中,比较延迟6小时开始的持续抗凝血酶III(AT)输注与生理盐水输注及单次弹丸AT注射的疗效。持续AT输注组7天生存率65%,显著高于生理盐水组的29%(n=21,P=0.018)和单次注射AT组的19%(n=21,P=0.003)。持续AT输注减轻了肝脏损伤,但未减轻肾脏或肺损伤;血管渗漏和炎症细胞因子仅在肝脏中被抑制。作者认为肝脏在腹腔脓毒症中可能因细菌聚集和凝血酶生成而关键,AT可能通过减轻凝血酶诱导的血管渗漏、炎症和肝损伤发挥保护作用,但因其他器官未受保护,AT可能需要与保护不同器官的药物联合使用。

要点

  • CLP脓毒症小鼠延迟6小时持续输注AT,7天生存率65%,显著高于生理盐水输注的29%(n=21,P=0.018)。
  • 延迟持续AT输注7天生存率65%,显著高于单次弹丸AT注射的19%(n=21,P=0.003)。
  • 持续AT输注减轻肝脏损伤,但未减轻肾脏或肺损伤;血管渗漏和炎症细胞因子仅在肝脏中被抑制。
  • 48小时时细菌和凝血酶在肝脏聚集最高,AT未改变器官细菌计数。
  • 作者认为肝脏在腹腔脓毒症中可能关键,AT可能通过减轻凝血酶诱导的血管渗漏、炎症和肝损伤发挥保护作用,但因其他器官未受保护,AT可能需要与保护不同器官的药物联合使用。

适用人群与场景

  • 小鼠盲肠结扎穿孔(CLP)脓毒症模型,在CLP手术后置入含AT或生理盐水的渗透泵。

处置流程与药物剂量

  • 在CLP手术时置入含AT或生理盐水的渗透泵,建立并验证脓毒症诱导与治疗之间约6小时的延迟。
  • 延迟6小时开始持续AT输注,并与单次弹丸AT注射进行比较。

研究设计与关键结果

  • 研究类型为动物实验(小鼠CLP脓毒症模型),比较延迟6小时持续AT输注与生理盐水输注及单次弹丸AT注射。
  • 延迟6小时持续AT输注组7天生存率65%,显著高于生理盐水输注组的29%(n=21,P=0.018)。
  • 延迟6小时持续AT输注组7天生存率65%,显著高于单次弹丸AT注射组的19%(n=21,P=0.003)。
  • 延迟持续AT输注减轻肝脏损伤,但未减轻肾脏或肺损伤;血管渗漏和炎症细胞因子仅在肝脏中被抑制。
  • 48小时时细菌和凝血酶在肝脏聚集最高;AT未改变器官细菌计数。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠CLP脓毒症模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为肝脏在腹腔脓毒症中可能因细菌聚集和后续凝血酶生成而关键;AT可能通过减轻凝血酶诱导的血管渗漏、炎症和肝损伤发挥保护作用;因其他器官未受保护,AT可能需要与保护不同器官的药物联合使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Bolus antithrombin III (AT) improved sepsis/organ dysfunction and survival in lipopolysaccharide/monomicrobial infusion pretreatment animal models; however, AT failed in clinical trials. Because insults and drug administration schedules differed between preclinical and clinical settings, we re-examined AT using a clinically relevant polymicrobial insult (cecal ligation and puncture, CLP) and a new method to continuously infuse AT after animals became ill.

METHODS: Mice were catheterized with saline-filled osmotic minipumps. During CLP surgery we inserted AT- or saline-containing minipumps. We created and validated a ~6 h delay between sepsis induction and treatment. We compared delayed, continuous AT infusion with a conventional bolus AT injection using survival studies and 48-h studies.

RESULTS: 6-h delayed, continuous AT infusion significantly improved 7-d survival versus saline infusion (65% vs. 29%, n = 21, P = 0.018) and versus a single injection of AT (65% vs. 19%, n = 21, P = 0.003). Delayed, continuous AT attenuated liver but not kidney or lung injury. Vascular leakage and inflammatory cytokines were suppressed only in liver. The highest accumulation of bacteria and thrombin at 48 h was in liver. AT did not change organ bacterial counts.

CONCLUSIONS: Delayed, continuous AT infusion improved 7-d survival after CLP compared to single bolus AT injection or continuous vehicle. Liver may be critical in abdominal sepsis because of bacterial accumulation and subsequent thrombin generation. AT may be protective due to attenuation of thrombin-induced vascular leakage, inflammation, and liver injury during CLP sepsis. Because other organs were unprotected, AT may be combined with drugs protecting different organs.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Hayase N, Chari RR, Dos Santos AAC, et al. Continuous Antithrombin III Infusion in a Clinically Relevant Sepsis Model. Shock. 2025. PMID: 40663443. doi:10.1097/SHK.0000000000002648

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。